BioMarin Pharmaceutical. BioMarin's Biologics license application for valoctocogene roxaparvovec accepted for Priority Review by FDA with review action date of August 21, 2020. February 20, 2020. https://investors.biomarin.com/2020-02-20-BioMarins-Biologics-License-Application-for-Valoctocogene-Roxaparvovec-Accepted-for-Priority-Review-by-FDA-with-Review-Action-Date-of-August-21-2020 (last accessed February26, 2020).
2.
StantonD, VinluanF. AveXis “flexible” NC plant a step closer to fully internal gene therapy network. February 24, 2020. https://bioprocessintl.com/bioprocess-insider/facilities-capacity/avexis-flexible-nc-plant-a-step-closer-to-fully-internal-gene-therapy-network/ (last accessed February26, 2020).
3.
Office of North Carolina Governor Roy Cooper. Governor Cooper celebrates Durham ribbon-cutting for AveXis. February 20, 2020. https://governor.nc.gov/news/governor-cooper-celebrates-durham-ribbon-cutting-avexis (last accessed February26, 2020).
4.
North Carolina Biotechnology Center. Audentes Therapeutics unveils $110m, 209-job gene therapy facility in Sanford. February 18, 2020. https://www.ncbiotech.org/news/audentes-therapeutics-unveils-110m-209-job-gene-therapy-facility-sanford (last accessed February26, 2020).
5.
Cehajic-KapetanovicJ, XueK, Martinez-Fernandez de la Camara C, et al.Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med, 2020 Feb 24 [Epub ahead of print]; DOI: 10.1038/s41591-020-0763-1.
6.
University of Oxford. Gene therapy shows promise in tackling common cause of childhood blindness. February 26, 2020. www.ox.ac.uk/news/2020-02-26-gene-therapy-shows-promise-tackling-common-cause-childhood-blindness (last accessed February26, 2020).
7.
bluebird bio. bluebird bio reports fourth quarter and full year 2019 financial results and highlights operational progress. February 18, 2020. http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-reports-fourth-quarter-and-full-year-2019-financial (last accessed February26, 2020).
8.
bluebird bio. bluebird bio announces launch in Germany of Zynteglo™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β0/β0 genotype. January 13, 2020. http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-launch-germany-zynteglotm-autologous-cd34 (last accessed February26, 2020).
9.
The Institute for Gene Therapies. New Institute launched to ensure the U.S. healthcare system is ready for gene therapies. February 19, 2020. https://www.businesswire.com/news/home/20200219005526/en/New-Institute-Launched-Ensure-U.S.-Healthcare-System (last accessed February26, 2020).
